• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病和轻度认知障碍中脑促红细胞生成素受体的表达

Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment.

作者信息

Assaraf Michael I, Diaz Zuanel, Liberman Adrienne, Miller Wilson H, Arvanitakis Zoe, Li Yan, Bennett David A, Schipper Hyman M

机构信息

Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada.

出版信息

J Neuropathol Exp Neurol. 2007 May;66(5):389-98. doi: 10.1097/nen.0b013e3180517b28.

DOI:10.1097/nen.0b013e3180517b28
PMID:17483696
Abstract

Cellular mechanisms conferring neuroprotection in the brains of patients with Alzheimer disease (AD) remain incompletely understood. Erythropoietin (Epo) and the erythropoietin receptor (EpoR) are expressed in neural tissues and protect against oxidative and other stressors in various models of brain injury and disease. Our objective in this study was to determine whether EpoR is upregulated in the brains of persons with sporadic AD and mild cognitive impairment (MCI). Postmortem hippocampus and temporal cortex from subjects with AD, MCI, and no cognitive impairment (NCI) were procured from the Religious Orders Study. Total immunoreactive EpoR protein was determined by Western blotting. Astrocytes expressing immunoreactive EpoR were quantified in 4 temporal and 6 hippocampal regions, and correlated with clinical, neuropsychologic, and neuropathologic indices. Total immunoreactive EpoR protein was markedly increased in AD and MCI temporal cortex versus NCI tissues. Composite measures of glial EpoR expression in temporal cortex layers I to IV were significantly greater in the MCI group compared with the NCI and AD groups. Hippocampal EpoR scores were increased in persons with MCI and AD relative to those with NCI. There was substantial subregional heterogeneity in disease-related EpoR expression patterns in AD and MCI temporal cortex and hippocampus. There was no association of EpoR-positive astrocytes with summary measures of global cognition or AD pathology. We conclude that upregulation of EpoR in temporal cortical and hippocampal astrocytes is an early, potentially neuroprotective, event in the pathogenesis of sporadic AD.

摘要

阿尔茨海默病(AD)患者大脑中赋予神经保护作用的细胞机制仍未完全明确。促红细胞生成素(Epo)及其受体(EpoR)在神经组织中表达,并在各种脑损伤和疾病模型中抵御氧化应激及其他应激源。本研究的目的是确定EpoR在散发性AD和轻度认知障碍(MCI)患者大脑中是否上调。从宗教团体研究中获取AD、MCI和无认知障碍(NCI)受试者的死后海马体和颞叶皮质。通过蛋白质免疫印迹法测定总免疫反应性EpoR蛋白。对4个颞叶和6个海马区中表达免疫反应性EpoR的星形胶质细胞进行定量,并与临床、神经心理学和神经病理学指标相关联。与NCI组织相比,AD和MCI颞叶皮质中的总免疫反应性EpoR蛋白显著增加。与NCI组和AD组相比,MCI组颞叶皮质I至IV层中胶质细胞EpoR表达的综合指标显著更高。与NCI患者相比,MCI和AD患者的海马EpoR评分升高。AD和MCI颞叶皮质及海马中与疾病相关的EpoR表达模式存在显著的亚区域异质性。EpoR阳性星形胶质细胞与整体认知或AD病理学的综合指标之间无关联。我们得出结论,颞叶皮质和海马星形胶质细胞中EpoR的上调是散发性AD发病机制中的一个早期、潜在的神经保护事件。

相似文献

1
Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment.阿尔茨海默病和轻度认知障碍中脑促红细胞生成素受体的表达
J Neuropathol Exp Neurol. 2007 May;66(5):389-98. doi: 10.1097/nen.0b013e3180517b28.
2
Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment.阿尔茨海默病和轻度认知障碍中胶质细胞血红素加氧酶-1的表达
Neurobiol Aging. 2006 Feb;27(2):252-61. doi: 10.1016/j.neurobiolaging.2005.01.016. Epub 2005 Apr 15.
3
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.轻度认知障碍老年受试者海马体和额叶皮质中胆碱乙酰转移酶活性上调。
Ann Neurol. 2002 Feb;51(2):145-55. doi: 10.1002/ana.10069.
4
Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment.轻度认知障碍老年受试者额叶和颞叶皮质中突触蛋白的差异表达。
J Neuropathol Exp Neurol. 2006 Jun;65(6):592-601. doi: 10.1097/00005072-200606000-00007.
5
Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging.轻度认知障碍、阿尔茨海默病与正常衰老之间的病理学及烟碱受体结合差异
Arch Neurol. 2006 Dec;63(12):1771-6. doi: 10.1001/archneur.63.12.1771.
6
Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease.轻度认知障碍和早期阿尔茨海默病患者中含有trkA免疫反应性的基底核神经元缺失。
J Comp Neurol. 2000 Nov 6;427(1):19-30. doi: 10.1002/1096-9861(20001106)427:1<19::aid-cne2>3.0.co;2-a.
7
Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology.轻度认知障碍个体海马体中的胆碱能可塑性:与阿尔茨海默病神经病理学的相关性
J Alzheimers Dis. 2003 Feb;5(1):39-48. doi: 10.3233/jad-2003-5106.
8
Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease.tau 蛋白在轻度认知障碍和阿尔茨海默病中的积累。
J Neuropathol Exp Neurol. 2011 Sep;70(9):788-98. doi: 10.1097/NEN.0b013e31822c62cf.
9
Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease.阿尔茨海默病中胆碱能基底前脑神经元的α7烟碱受体上调
Arch Neurol. 2007 Dec;64(12):1771-6. doi: 10.1001/archneur.64.12.1771.
10
Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor.促红细胞生成素可改善创伤性脑损伤小鼠的组织学和功能结局,而不依赖于神经促红细胞生成素受体。
J Neurotrauma. 2010 Jan;27(1):205-15. doi: 10.1089/neu.2009.1001.

引用本文的文献

1
Tactile discrimination as a diagnostic indicator of cognitive decline in patients with mild cognitive impairment: A narrative review.触觉辨别作为轻度认知障碍患者认知衰退的诊断指标:一项叙述性综述。
Heliyon. 2024 May 14;10(10):e31256. doi: 10.1016/j.heliyon.2024.e31256. eCollection 2024 May 30.
2
Advanced patient-specific microglia cell models for pre-clinical studies in Alzheimer's disease.用于阿尔茨海默病临床前研究的先进的患者特异性小胶质细胞模型。
J Neuroinflammation. 2024 Feb 15;21(1):50. doi: 10.1186/s12974-024-03037-3.
3
Chorioamnionitis disrupts erythropoietin and melatonin homeostasis through the placental-fetal-brain axis during critical developmental periods.
绒毛膜羊膜炎在关键发育阶段通过胎盘-胎儿-脑轴破坏促红细胞生成素和褪黑素的稳态。
Front Physiol. 2023 Jul 20;14:1201699. doi: 10.3389/fphys.2023.1201699. eCollection 2023.
4
Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.阿尔茨海默病是人类大脑自然老化的固有组成部分:综合视角。
Free Neuropathol. 2022 Jul 8;3:17. doi: 10.17879/freeneuropathology-2022-3806. eCollection 2022 Jan.
5
Pathogenesis of Chronic Kidney Disease Is Closely Bound up with Alzheimer's Disease, Especially via the Renin-Angiotensin System.慢性肾脏病的发病机制与阿尔茨海默病密切相关,尤其是通过肾素-血管紧张素系统。
J Clin Med. 2023 Feb 12;12(4):1459. doi: 10.3390/jcm12041459.
6
Reactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer's disease.反应性星形胶质细胞:阿尔茨海默病病理和临床特征的交汇点。
Ageing Res Rev. 2021 Jul;68:101335. doi: 10.1016/j.arr.2021.101335. Epub 2021 Mar 31.
7
Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease.重组人促红细胞生成素及其分子变体对阿尔茨海默病病理特征保护作用的当前证据
Pharmaceuticals (Basel). 2020 Nov 26;13(12):424. doi: 10.3390/ph13120424.
8
Neuroprotective effects of EpoL against oxidative stress induced by soluble oligomers of Aβ peptide.EpoL 对 Aβ 肽可溶性寡聚物诱导的氧化应激的神经保护作用。
Redox Biol. 2019 Jun;24:101187. doi: 10.1016/j.redox.2019.101187. Epub 2019 Apr 2.
9
The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease.促红细胞生成素治疗阿尔茨海默病的前景与挑战。
Neuromolecular Med. 2019 Mar;21(1):12-24. doi: 10.1007/s12017-019-08524-y. Epub 2019 Jan 17.
10
Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.用于阿尔茨海默病的穿透血脑屏障的双功能促红细胞生成素-转铁蛋白受体抗体融合蛋白。
Mol Pharm. 2018 Nov 5;15(11):4963-4973. doi: 10.1021/acs.molpharmaceut.8b00594. Epub 2018 Oct 9.